These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1134191)

  • 21. Influence of pregnancy and folic acid on phenytoin metabolism by rat liver microsomes.
    Blake DA; Collins JM; Miyasaki BC; Cohen F
    Drug Metab Dispos; 1978; 6(3):246-50. PubMed ID: 26544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion of phenytoin to reactive metabolites in rat liver microsomes.
    Billings RE; Milton SG
    Adv Exp Med Biol; 1986; 197():931-9. PubMed ID: 3020938
    [No Abstract]   [Full Text] [Related]  

  • 23. Interactions between folate metabolism, phenytoin metabolism, and liver microsomal cytochrome P450.
    Billings RE
    Drug Nutr Interact; 1984; 3(1):21-32. PubMed ID: 6510238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased microsomal irreversible binding of phenytoin by valproic acid.
    Wang SL; Lai ML; Huang JD
    Biochem Pharmacol; 1991 Aug; 42(5):1143-4. PubMed ID: 1872899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of safrazine, a monoamine oxidase inhibitor bearing a hydrazine-terminal, on phenytoin metabolism in isolated rat hepatocytes.
    Eto S; Noda H; Minemoto M; Noda A
    Chem Pharm Bull (Tokyo); 1988 Jan; 36(1):456-8. PubMed ID: 3378307
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies on the metabolism of diphenylhydantoin in mice.
    Gerber N; Arnold K
    J Pharmacol Exp Ther; 1969 May; 167(1):77-90. PubMed ID: 5772752
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolism in vitro of 5,5-diphenylhydantoin.
    Gabler WL; Hubbard GL
    Biochem Pharmacol; 1972 Nov; 21(22):3071-3. PubMed ID: 4405453
    [No Abstract]   [Full Text] [Related]  

  • 28. Sex differences in rats in the metabolism of phenytoin to 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin.
    Billings RE
    J Pharmacol Exp Ther; 1983 Jun; 225(3):630-6. PubMed ID: 6864524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
    Brown HS; Chadwick A; Houston JB
    Drug Metab Dispos; 2007 Nov; 35(11):2119-26. PubMed ID: 17724064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metabolism of drugs in isolated rat hepatocytes. A comparison with in vivo drug metabolism and drug metabolism in subcellular liver fractions.
    Billings RE; McMahon RE; Ashmore J; Wagle SR
    Drug Metab Dispos; 1977; 5(6):518-26. PubMed ID: 21776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The distribution and metabolism of Dilantin in non-pregnant, pregnant and fetal rats.
    Gabler WL; Falace D
    Arch Int Pharmacodyn Ther; 1970 Mar; 184(1):45-58. PubMed ID: 5452323
    [No Abstract]   [Full Text] [Related]  

  • 32. An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin.
    Riley RJ; Maggs JL; Lambert C; Kitteringham NR; Park BK
    Br J Clin Pharmacol; 1988 Nov; 26(5):577-88. PubMed ID: 3207562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
    Ashforth EI; Carlile DJ; Chenery R; Houston JB
    J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical and genetic factors regulating dilantin metabolism in man.
    Kutt H
    Ann N Y Acad Sci; 1971 Jul; 179():705-22. PubMed ID: 4105796
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of passive transfer and induction of gamma (type II immune) interferon preparations on the metabolism of diphenylhydantoin by murine cytochrome P-450.
    Harned CL; Nerland DE; Sonnenfeld G
    J Interferon Res; 1982; 2(1):5-10. PubMed ID: 6180105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes.
    Komatsu T; Yamazaki H; Nakajima M; Yokoi T
    Biochem Pharmacol; 2002 Jun; 63(12):2081-90. PubMed ID: 12110367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-dimensional high-performance liquid chromatographic method to assay p-hydroxyphenylphenylhydantoin enantiomers in biological fluids and stereoselectivity of enzyme induction in phenytoin metabolism.
    Hsieh CY; Huang JD
    J Chromatogr; 1992 Mar; 575(1):109-15. PubMed ID: 1517287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism of phenytoin in teratogenesis-susceptible and -resistant strains of mice.
    Hansen DK; Hodes ME
    Drug Metab Dispos; 1983; 11(1):21-4. PubMed ID: 6132790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nafimidone, an imidazole anticonvulsant, and its metabolite as potent inhibitors of microsomal metabolism of phenytoin and carbamazepine.
    Kapetanovic IM; Kupferberg HJ
    Drug Metab Dispos; 1984; 12(5):560-4. PubMed ID: 6149905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further observations on the interactions between phenobarbital and diphenylhydantoin during chronic treatment in the rat.
    Rizzo M; Morselli PL; Garattini S
    Biochem Pharmacol; 1972 Feb; 21(4):449-54. PubMed ID: 5014504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.